{"nctId":"NCT01604850","briefTitle":"Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION)","startDateStruct":{"date":"2012-06"},"conditions":["Chronic Hepatitis C"],"count":202,"armGroups":[{"label":"SOF+RBV+placebo","type":"EXPERIMENTAL","interventionNames":["Drug: SOF","Drug: RBV","Drug: Placebo to match SOF","Drug: Placebo to match RBV"]},{"label":"SOF+RBV","type":"EXPERIMENTAL","interventionNames":["Drug: SOF","Drug: RBV"]}],"interventions":[{"name":"SOF","otherNames":["Sovaldi®","GS-7977","PSI-7977"]},{"name":"RBV","otherNames":[]},{"name":"Placebo to match SOF","otherNames":[]},{"name":"Placebo to match RBV","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Infection with HCV genotype 2 or 3\n* Had cirrhosis determination\n* Prior treatment failure\n* Screening laboratory values within defined thresholds\n* Subject had not been treated with any investigational drug or device within 30 days of the screening visit\n* Use of highly effective contraception methods if female of childbearing potential or sexually active male\n\nExclusion Criteria:\n\n* Prior exposure to an direct-acting antiviral targeting the HCV nonstructural protein (NS)5B polymerase\n* Pregnant or nursing female or male with pregnant female partner\n* Current or prior history of clinical hepatic decompensation\n* History of clinically significant illness or any other major medical disorder that may have interfered with subject treatment, assessment or compliance with the protocol\n* Excessive alcohol ingestion or significant drug abuse","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Achieving SVR12","description":"SVR12 was defined as HCV RNA \\< the lower limit of quantitation (LLOQ, ie, \\< 25 IU/mL) 12 weeks after cessation of therapy.\n\nFor the purposes of this efficacy analysis, the posttreatment period began after the end of active treatment (following Week 12 for the SOF+RBV+placebo arm, and Week 16 for the SOF+RBV arm).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.0","spread":null},{"groupId":"OG001","value":"72.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Adverse Events Leading to Permanent Discontinuation of Study Drug","description":"Adverse events which led to permanent discontinuation of study drug may or may not have been related to study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving SVR4","description":"SVR4 was defined as HCV RNA \\< LLOQ 4 weeks after cessation of therapy.\n\nFor the purposes of this efficacy analysis, the posttreatment period began after the end of active treatment (following Week 12 for the SOF+RBV+placebo arm, and Week 16 for the SOF+RBV arm).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.0","spread":null},{"groupId":"OG001","value":"76.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving SVR24","description":"SVR24 was defined as HCV RNA \\< LLOQ 24 weeks after cessation of therapy.\n\nFor the purposes of this efficacy analysis, the posttreatment period began after the end of active treatment (following Week 12 for the SOF+RBV+placebo arm, and Week 16 for the SOF+RBV arm).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null},{"groupId":"OG001","value":"71.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Viral Breakthrough","description":"Viral breakthrough was defined as HCV RNA ≥ LLOQ after having previously had HCV RNA \\< LLOQ while receiving treatment, confirmed with 2 consecutive values (second confirmation value could be posttreatment), or last available on-treatment measurement with no subsequent follow-up values.\n\nFor the purposes of this efficacy analysis, assessments were made during active treatment (up to Week 12 for the SOF+RBV+placebo arm, and Week 16 for the SOF+RBV arm).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Viral Relapse","description":"Viral relapse was defined as HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \\< LLOQ at end of treatment, confirmed with 2 consecutive values or last available posttreatment measurement.\n\nFor the purposes of this efficacy analysis, the posttreatment period began after the end of active treatment (following Week 12 for the SOF+RBV+placebo arm, and Week 16 for the SOF+RBV arm).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":103},"commonTop":["Fatigue","Headache","Insomnia","Nausea","Irritability"]}}}